FDA issues complete response letter to Replimune’s RP1 for melanoma
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) to Replimune Group’s biologics licence application…
Oncology
-
-
Merck’s strategic shift: acquires Terns for $6.7bn, targeting dominance in CML
On 25 March, Merck (MSD) announced the $6.7bn acquisition of Terns Pharmaceuticals via a subsidiary, as part of its strategic…
-
Improving early detection and treatment of liver cancer
Outcomes for liver cancer patients are highly stage dependent. Interventions designed to be curative, such as minimally invasive ablation, tumour…
-
Transient but transformative: Sanofi’s mRNA CAR-T enters in vivo race
In a recent article in Molecular Therapy, Sanofi presented preclinical data for an in vivo CAR-T platform that reengineers T…
-
Multiple Myeloma Awareness Month: the current and future landscape
March is Multiple Myeloma (MM) Awareness Month, which raises awareness, action, and amplifies the voices of individuals impacted by MM,…
-
Targeted therapies to join chemo as oncology treatment backbone
In recent years, the oncology sector has undergone a fundamental shift away from chemotherapy-dominant treatment towards the use of regimens…
-
Theranostics earmarked as “the future” of radiopharmaceuticals
As the oncology market enters a new era of growth, targeted therapies across several modalities are transforming the treatment paradigm.…
-
JPM26: AstraZeneca bids to accelerate oncology R&D with Modella AI acquisition
AstraZeneca has agreed to acquire Boston-based Modella AI as part of a strategy to speed up drug development across its…
-
JPM26: Revolution Medicines in spotlight as industry gears up for dealmaking spree
Revolution Medicines has dominated the build-up to the 2026 J.P. Morgan Healthcare Conference, as media reports swirl around a potential…
-
Aktis Oncology kicks 2026 IPO cycle off with $210m target
The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a…
